Phoenix Biotech Acquisition Stock Return On Asset

PBAXWDelisted Stock   0.06  0.0001  0.16%   
Phoenix Biotech Acquisition fundamentals help investors to digest information that contributes to Phoenix Biotech's financial success or failures. It also enables traders to predict the movement of Phoenix Stock. The fundamental analysis module provides a way to measure Phoenix Biotech's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Phoenix Biotech stock.
  
This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

Phoenix Biotech Acquisition Company Return On Asset Analysis

Phoenix Biotech's Return on Asset or ROA shows how effective is the management of the company in generating income from utilizing all of the assets at their disposal. It is a useful ratio to evaluate the performance of different departments of a company as well as to understand management performance over time.

Return On Asset

 = 

Net Income

Total Assets

More About Return On Asset | All Equity Analysis

Current Phoenix Biotech Return On Asset

    
  -0.0255  
Most of Phoenix Biotech's fundamental indicators, such as Return On Asset, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Phoenix Biotech Acquisition is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Return on Asset measures overall efficiency of a company in generating profits from its total assets. It is expressed as the percentage of profits earned per dollar of Asset. A low ROA typically means that a company is asset-intensive and therefore will needs more money to continue generating revenue in the future.
Competition

Based on the latest financial disclosure, Phoenix Biotech Acquisition has a Return On Asset of -0.0255. This is 94.57% lower than that of the Capital Markets sector and significantly lower than that of the Financials industry. The return on asset for all United States stocks is 81.79% lower than that of the firm.

Phoenix Return On Asset Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Phoenix Biotech's direct or indirect competition against its Return On Asset to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Phoenix Biotech could also be used in its relative valuation, which is a method of valuing Phoenix Biotech by comparing valuation metrics of similar companies.
Phoenix Biotech is currently under evaluation in return on asset category among its peers.

Phoenix Fundamentals

About Phoenix Biotech Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Phoenix Biotech Acquisition's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Phoenix Biotech using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Phoenix Biotech Acquisition based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in interest.
You can also try the Fundamentals Comparison module to compare fundamentals across multiple equities to find investing opportunities.

Other Consideration for investing in Phoenix Stock

If you are still planning to invest in Phoenix Biotech Acqu check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Phoenix Biotech's history and understand the potential risks before investing.
Portfolio Manager
State of the art Portfolio Manager to monitor and improve performance of your invested capital
FinTech Suite
Use AI to screen and filter profitable investment opportunities
Global Correlations
Find global opportunities by holding instruments from different markets
Balance Of Power
Check stock momentum by analyzing Balance Of Power indicator and other technical ratios
Funds Screener
Find actively-traded funds from around the world traded on over 30 global exchanges
Portfolio Suggestion
Get suggestions outside of your existing asset allocation including your own model portfolios
Latest Portfolios
Quick portfolio dashboard that showcases your latest portfolios
Pattern Recognition
Use different Pattern Recognition models to time the market across multiple global exchanges
Alpha Finder
Use alpha and beta coefficients to find investment opportunities after accounting for the risk